Drug information provided by: Merative, Micromedex®
Abemaciclib is used together with tamoxifen or an aromatase inhibitor (eg, anastrozole, exemestane, letrozole) to treat hormone receptor (HR)-positive, HER-2 negative, node-positive, early breast cancer with a high risk of coming back as determined by your doctor.
Abemaciclib is also used together with an aromatase inhibitor (eg, anastrozole, exemestane, letrozole) as initial hormonal treatment to treat men and postmenopausal women with hormone receptor (HR)-positive, HER-2 negative advanced (cancer that has worsened) or metastatic (cancer that has spread) breast cancer. It is also used alone or together with fulvestrant to treat HR-positive, HER-2 negative advanced or metastatic breast cancer in women who have received hormonal treatment or other cancer medicines that did not work well.
Abemaciclib belongs to the group of medicines called antineoplastics. It interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal cells may also be affected by the medicine, other unwanted effects will also occur. Some of these may be serious and must be reported to your doctor.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: May 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.